{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:43:42Z","timestamp":1790109822947,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10120-026-01736-9","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:44:42Z","timestamp":1775115882000},"page":"597-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Koichiro","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Shimozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-3859","authenticated-orcid":false,"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"3","key":"1736_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1736_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"10125","key":"1736_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000\u20132014 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018;391(10125):1023\u201375.","journal-title":"The Lancet"},{"key":"1736_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31\u201349.","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"9","key":"1736_CR5","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523\u20139.","journal-title":"Ann Oncol"},{"issue":"2","key":"1736_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9742","key":"1736_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"10418","key":"1736_CR8","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208.","journal-title":"Lancet"},{"issue":"suppl 2","key":"1736_CR9","volume":"44","author":"E Elimova","year":"2026","unstructured":"Elimova E, Rha SY, Shitara K, Liu T, Tabernero J, et al. Zanidatamab + chemotherapy (CT) \u00b1 tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01. J Clin Oncol. 2026;44(suppl 2):2026 (abstr LBA285).","journal-title":"J Clin Oncol"},{"issue":"2","key":"1736_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12029-022-00815-1","volume":"54","author":"S Marshall","year":"2023","unstructured":"Marshall S, Wakatsuki T, Takahari D, Matsushima T, Ishizuka N, Nakayama I, et al. Prognostic factors in patients with advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy: a cohort study. J Gastrointest Cancer. 2023;54(2):475\u201384.","journal-title":"J Gastrointest Cancer"},{"issue":"3","key":"1736_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00432-022-03966-7","volume":"149","author":"K Shimozaki","year":"2023","unstructured":"Shimozaki K, Shinozaki E, Yamamoto N, Imamura Y, Osumi H, Nakayama I, et al. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. J Cancer Res Clin Oncol. 2023;149(3):1273\u201383.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1736_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","volume":"8","author":"YY Janjigian","year":"2018","unstructured":"Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8(1):49\u201358.","journal-title":"Cancer Discov"},{"issue":"11","key":"1736_CR13","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","volume":"53","author":"T Wakatsuki","year":"2018","unstructured":"Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol. 2018;53(11):1186\u201395.","journal-title":"J Gastroenterol"},{"issue":"3","key":"1736_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s10120-018-0887-x","volume":"22","author":"S Yagi","year":"2019","unstructured":"Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2019;22(3):518\u201325.","journal-title":"Gastric Cancer"},{"issue":"6","key":"1736_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-024-02509-z","volume":"29","author":"T Wakatsuki","year":"2024","unstructured":"Wakatsuki T, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Goto M, et al. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab. Int J Clin Oncol. 2024;29(6):801\u201312.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"1736_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","volume":"18","author":"Y Kurokawa","year":"2015","unstructured":"Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18(4):691\u20137.","journal-title":"Gastric Cancer"},{"issue":"17","key":"1736_CR17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.19.03077","volume":"38","author":"A Makiyama","year":"2020","unstructured":"Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol. 2020;38(17):1919\u201327.","journal-title":"J Clin Oncol"},{"key":"1736_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41\u20139.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1736_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2019","unstructured":"Seo S, Ryu M-H, Park YS, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22(3):527\u201335.","journal-title":"Gastric Cancer"},{"issue":"10","key":"1736_CR20","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s00595-020-02011-9","volume":"50","author":"R Takahashi","year":"2020","unstructured":"Takahashi R, Nunobe S, Osumi H, Takahari D, Yamamoto N, Ida S, et al. Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer. Surg Today. 2020;50(10):1240\u20138.","journal-title":"Surg Today"},{"issue":"12","key":"1736_CR21","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/ijc.30408","volume":"139","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer. 2016;139(12):2859\u201364.","journal-title":"Int J Cancer"},{"issue":"20","key":"1736_CR22","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1736_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody\u2013drug conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull Tokyo. 2019;67(3):173\u201385.","journal-title":"Chem Pharm Bull Tokyo"},{"issue":"7","key":"1736_CR24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346.","journal-title":"Cancer Sci"},{"issue":"8","key":"1736_CR25","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","volume":"141","author":"N Takegawa","year":"2017","unstructured":"Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, et al. DS-8201a, a new HER2-targeting antibody\u2013drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141(8):1682\u20139.","journal-title":"Int J Cancer"},{"issue":"25","key":"1736_CR26","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"1736_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, Lonardi S, de la Fouchardi\u00e8re C, Coutzac C, et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med. 2025;393(4):336\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"1736_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10120-015-0502-3","volume":"19","author":"N Tominaga","year":"2016","unstructured":"Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19(2):553\u201360.","journal-title":"Gastric Cancer"},{"issue":"3","key":"1736_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1736_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10120-024-01555-w","volume":"28","author":"H Kawakami","year":"2025","unstructured":"Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, et al. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer. 2025;28(1):51\u201361.","journal-title":"Gastric Cancer"},{"key":"1736_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082247","author":"T Matsumoto","year":"2022","unstructured":"Matsumoto T, Yamamura S, Ikoma T, Kurioka Y, Doi K, Boku S, et al. Real-world data of Trastuzumab Deruxtecan for advanced gastric cancer: a multi-institutional retrospective study. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11082247.","journal-title":"J Clin Med"},{"issue":"19","key":"1736_CR32","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","volume":"32","author":"T Satoh","year":"2014","unstructured":"Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized phase III study. J Clin Oncol. 2014;32(19):2039\u201349.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1736_CR33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1736_CR34","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1200\/JCO.20.02761","volume":"39","author":"I Haffner","year":"2021","unstructured":"Haffner I, Schierle K, Raim\u00fandez E, Geier B, Maier D, Hasenauer J, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39(13):1468\u201378.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1736_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/cas.12886","volume":"107","author":"K Kanayama","year":"2016","unstructured":"Kanayama K, Imai H, Yoneda M, Hirokawa YS, Shiraishi T. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: a comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci. 2016;107(4):536\u201342.","journal-title":"Cancer Sci"},{"issue":"5","key":"1736_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.humpath.2013.12.010","volume":"45","author":"T Wang","year":"2014","unstructured":"Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol. 2014;45(5):970\u20135.","journal-title":"Hum Pathol"},{"issue":"18","key":"1736_CR37","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-22-3769","volume":"29","author":"SB Maron","year":"2023","unstructured":"Maron SB, Chatila W, Walch H, Chou JF, Ceglia N, Ptashkin R, et al. Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer. Clin Cancer Res. 2023;29(18):3633\u201340.","journal-title":"Clin Cancer Res"},{"issue":"40","key":"1736_CR38","doi-asserted-by":"publisher","first-page":"66020","DOI":"10.18632\/oncotarget.11791","volume":"7","author":"F Ma","year":"2016","unstructured":"Ma F, Zhu W, Guan Y, Yang L, Xia X, Chen S, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget. 2016;7(40):66020\u201331.","journal-title":"Oncotarget"},{"issue":"7","key":"1736_CR39","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","volume":"68","author":"DS Wang","year":"2019","unstructured":"Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019;68(7):1152\u201361.","journal-title":"Gut"},{"key":"1736_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2017.10.032","volume":"88","author":"H Wang","year":"2018","unstructured":"Wang H, Li B, Liu Z, Gong J, Shao L, Ren J, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;88:92\u2013100.","journal-title":"Eur J Cancer"},{"key":"1736_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","volume":"43","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhao C, Chang L, Jia R, Liu R, Zhang Y, et al. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019;43:261\u20139.","journal-title":"EBioMedicine"},{"issue":"4","key":"1736_CR42","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/annonc\/mdy034","volume":"29","author":"ST Kim","year":"2018","unstructured":"Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018;29(4):1037\u201348.","journal-title":"Ann Oncol"},{"key":"1736_CR43","doi-asserted-by":"publisher","first-page":"175883592513673","DOI":"10.1177\/17588359251367344","volume":"17","author":"H Osumi","year":"2025","unstructured":"Osumi H, Wakatsuki T, Ooki A, Chin K, Shoji H, Ogura M, et al. Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High). Ther Adv Med Oncol. 2025;17:17588359251367344.","journal-title":"Ther Adv Med Oncol"},{"key":"1736_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102683","volume":"124","author":"D Ciardiello","year":"2024","unstructured":"Ciardiello D, Mauri G, Sartore-Bianchi A, Siena S, Zampino MG, Fazio N, et al. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review. Cancer Treat Rev. 2024;124:102683.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"1736_CR45","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342.","journal-title":"Nat Med"},{"key":"1736_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1508","volume":"35","author":"H Osumi","year":"2024","unstructured":"Osumi H, Wakatsuki T, Yamamoto N, Ooki A, Chin K, Shoji H, et al. 1442P correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: a phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy. Ann Oncol. 2024;35:S897.","journal-title":"Ann Oncol"},{"issue":"11","key":"1736_CR47","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau H-T, Prokharau A, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437\u201348.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1736_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab Deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a Trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1736_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10120-024-01560-z","volume":"28","author":"A Jubashi","year":"2025","unstructured":"Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, et al. Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer. Gastric Cancer. 2025;28(1):63\u201373.","journal-title":"Gastric Cancer"},{"key":"1736_CR50","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/DDDT.S508773","volume":"19","author":"D Liao","year":"2025","unstructured":"Liao D, Zhang J, Yan T, Chen Y, Fu Y, Xie N, et al. A systematic review of mechanisms, incidence, and management of Trastuzumab Deruxtecan induced ILD\/pneumonitis in solid tumors. Drug Des Devel Ther. 2025;19:1655\u201368.","journal-title":"Drug Des Devel Ther"},{"key":"1736_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","journal-title":"ESMO Open"},{"key":"1736_CR52","doi-asserted-by":"crossref","unstructured":"Wekking D, Porcu M, Pellegrino B, Lai E, Mura G, Denaro N, et al. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open. 2023;8(6).","DOI":"10.1016\/j.esmoop.2023.102043"},{"issue":"4","key":"1736_CR53","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/cpt.2291","volume":"110","author":"O Yin","year":"2021","unstructured":"Yin O, Iwata H, Lin CC, Tamura K, Watanabe J, Wada R, et al. Exposure-response relationships in patients with HER2-Positive metastatic breast cancer and other solid tumors treated with Trastuzumab Deruxtecan. Clin Pharmacol Ther. 2021;110(4):986\u201396.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01736-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01736-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01736-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:23:15Z","timestamp":1781644995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01736-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1736"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01736-9","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study involved human participants and was approved by the Certified Review Board of the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (IRB number: 2023-GB-015). The protocol was described on the hospital website, and subjects were provided the opportunity to opt-out; therefore, no additional consent was required from patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}